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Simple Summary: Multiple myeloma is the second most common hematological cancer and is still
incurable. Although enhanced understanding of the disease background and the development of
novel therapeutics during the last decade resulted in a significant increase of overall survival time,
almost all patients relapse and finally succumb to their disease. Therefore, novel medications are
urgently needed. Nature-derived compounds still account for the majority of new therapeutics and
especially for the treatment of cancer often serve as lead compounds in drug development. The
present review summarizes the data on plant natural products with in vitro and in vivo activity
against multiple myeloma until the end of 2020, focusing on their structure–activity relationship as
well as the investigated pathways and involved molecules.
Abstract: A literature search on plant natural products with antimyeloma activity until the end of
2020 resulted in 92 compounds with effects on at least one human myeloma cell line. Compounds
were divided in different compound classes and both their structure–activity-relationships as well as
eventual correlations with the pathways described for Multiple Myeloma were discussed. Each of the
major compound classes in this review (alkaloids, phenolics, terpenes) revealed interesting candidates,
such as dioncophyllines, a group of naphtylisoquinoline alkaloids, which showed pronounced
and selective induction of apoptosis when substituted in position 7 of the isoquinoline moiety.
Interestingly, out of the phenolic compound class, two of the most noteworthy constituents belong to
the relatively small subclass of xanthones, rendering this group a good starting point for possible
further drug development. The class of terpenoids also provides noteworthy constituents, such
as the highly oxygenated diterpenoid oridonin, which exhibited antiproliferative effects equal to
those of bortezomib on RPMI8226 cells. Moreover, triterpenoids containing a lactone ring and/or
quinone-like substructures, e.g., bruceantin, whitaferin A, withanolide F, celastrol, and pristimerin,
displayed remarkable activity, with the latter two compounds acting as inhibitors of both NF-κB and
proteasome chymotrypsin-like activity.
Keywords: STAT3; MM-CSC; antimyeloma; proteasome inhibitor; cancer; leukemia; polyphenolic;
flavonoid; caspase; tumor
1. Introduction
Multiple myeloma (MM) is a clinically heterogeneous plasma cell cancer that is mostly
restricted to the bone marrow. It accounts for almost 10% of all blood cancers and shows
considerable variations in the response to treatment [1]. This leads to overall response
rates that vary from a few months to more than a decade [2]. As the disease progresses,
patients suffer from a repeating pattern of remission and relapse as they cycle through
different therapeutic options. Typically, remission periods become shorter and tumor cells
increase their aggressiveness [3]. Eventually, most patients die because of refractory disease.
Therefore, novel therapeutic approaches are urgently needed.
For many years, treatment regimens consisted of alkylating agents, anthracyclines
and corticosteroids, and overall survival was poor (average three years) [4]. The introduc-
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tion of bone marrow transplantation in the 1990s was a successful step in enhancing life
expectancy. Landmarks in myeloma therapy in the last decade were the development of
proteasome inhibitors such as bortezomib and carfilzomib as well as the introduction of
immunomodulatory drugs such as thalidomide, lenalidomide, and pomalidomide, which
are currently standard of care [5]. Recently, therapies including monoclonal antibodies
against CD38 and B cell maturation antigen (BCMA) as well as CAR T cell therapies reveal
promising results [6,7].
MM is a disease with high levels of both inter- and intra-patient heterogeneity [8,9].
At least seven subtypes have been identified corresponding to genetic lesions that are
regarded as the initiating events in tumorigenesis. Beside genetic alterations, the tumor
microenvironment plays a significant role in this disease [10]. Myeloma cells are mostly
restricted to the bone marrow and heavily depend on cellular crosstalk. They modulate
adjacent cells to support their growth and drug resistance via production of cytokines,
chemokines, and other cofactors. These messengers trigger signaling cascades including
NF-κB, JAK2/STAT3, Hedgehog, Notch, TGFβ-, and Wnt pathway [11]. Furthermore,
molecules within the RAS/RAF/MEK/ERK as well as the PI3K/AKT-pathway are evolv-
ing as promising therapeutic targets [12].
Natural compounds often constitute the basis for the development of effective thera-
pies. In the last four decades, about a quarter of all approved drugs were of natural origin
(not including biologicals) and another quarter was inspired by nature, e.g., by using the
molecules’ pharmacophore [13]. This is even more the case for anticancer drugs, where
25% of the approved compounds were of natural origin or nature-derived and 38% were
mimicked by organic synthesis, meaning that drug discovery from nature is still the most
common way for the development of novel therapeutics.
However, secondary (or specialized) plant metabolites do not only serve as potential
lead structures for new drugs but in many cases are also part of our nutrition, not with
respect to their caloric value but as accompanying substances with our intake of fruits
and vegetables. The regular consumption of these substances might well play a role in
the prevention of tumor development, given the fact that they are present in considerable
concentrations [14]. Therefore, the present review not only aims to discuss antimyeloma
plant natural products with respect to their eventual use as therapeutics or structural lead
compounds, but also with regard to their dietary function.
2. Methods
A literature search was carried out for the time frame from 1945–2020 using the Web
of Science citation indexing service. Thereby, the term “multiple myeloma” was used in
combination with the words “natural product”, “natural compound”, “natural substance”,
“naturally occurring”, or “plant-derived” resulting in 552 publications. Additionally, the
term “multiple myeloma” was searched alone, and the results were reduced to the field
of plant science, giving 36 hits. Duplicates were removed and the remaining publications
were reviewed by title, abstract, and text resulting in 180 publications.
Literature data was evaluated for the use of appropriate cell lines and techniques
ignoring studies of extracts without identifying single molecules. Moreover, only those
compounds were included into this review, which were tested on at least one human
myeloma cell line (also neglecting cell lines that are EBV-transformed B-lymphocytes).
Thus, a total of 92 natural products with reported antimyeloma activity were obtained and
divided into compound classes (alkaloids, phenolics, and terpenes) and, depending on
the number of compounds, into several subclasses, thereby defining the structure of this
review. Compound names (mostly trivial names) and configurations were taken “as is”
from the original publications and names of the investigated plant species were checked
using “The Plant List” [15].
The data discussed in this review is additionally summarized in two tables. Table 1
gives an overview of the investigated myeloma cell lines as well as the IC50 or EC50 values
obtained from assays of the compounds’ antiproliferative effects or measurements for the
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inductions of apoptosis. Table 2 summarizes the investigated pathways and regulated
molecules. Moreover, reported synergisms or inhibitions with other drugs used for the
treatment of myeloma as well as eventual tests on primary myeloma cells are listed in
this table. Additionally, applied tumor models and investigations of cells of the tumor-
microenvironment are indicated.
Table 1. Overview on reported measurements for inhibition of cell proliferation and for induction of apoptosis. Major cell
lines are listed together with IC50 values for antiproliferative effects and the time of incubation (in parenthesis) or EC50
values for the induction of apoptosis, the latter indicated in italics. Additional cell lines are listed in the second to last
column with the respective IC50 or EC50 as well as the time of incubation (both in parenthesis). All concentrations are given
in µmol/L. The last column indicates the section of this review, in which the compounds are discussed in detail.










27.3 (24 h) >50 (24 h) 37.3 (24 h) 3.3.3
25-O-acetylcimigenol-3-
O-β-D-xylopyranoside 30.6 (24 h) 39.7 (24 h) >50 (24 h) 3.3.3
6-acetylfredericone B 21.6 (24 h) 3.3.2
23-O-acetylshengmanol-
3-O-β-D-xylopyranoside x x x 3.3.3
actein x x x 3.3.3






Ancistrocladisine A 4.8 (72 h) 3.1.1
Andrographolide ~25 (18 h) ~25 (18 h) 3.3.2
6-angeloylplenolin ~7.5 (48 h) ~7.5 (48 h) ~7.5 (48 h) 3.3.1




Arctiin x x <20 (24 h) 3.2.2
Asiaticoside KM3 (12, 48 h) 3.3.3
Baicalein ~60 (24 h) 3.2.6
Berberine 135 (48 h) x 3.1.1
Bergamottin x x 3.2.3








Bruceantin 0.115(24 h) 0.013 (24 h) 0.049 (24 h) 3.3.3
Butein 30–40(72 h) ~10 (72 h) 3.2.5
Capillarisin 200 (36 h) 3.2.3
Capsaicin x 5 (72 h) 3.1.2
Cardamonin ~60 (24 h)~10 (48 h)
~45 (24 h)
15 (48 h) 3.2.5
Celastrol 0.47 (24 h) 3.3.3
Cnicin ~1 (72 h) 1–3 (72 h) 1–3 (72 h) 1–3 (72 h) ~3.5 (72 h) LP1 (1–3, 72 h)MM1R (1–3, 72 h) 3.3.1
Coleon G 38.4 (24 h) 3.3.2
Coleon O 8.4 (24 h) 3.3.2
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Table 1. Cont.






Curcumin 5–10(72 h) x
10–25





























(24 h) 25.97 (24 h) 15.02 (24 h) 3.2.5
5,3′-dihydroxy-3,6,7,8,4′-
pentamethoxyflavone ~50 (48 h) ~50 (72 h) ~50 (48 h)
3.2.6
Dioncophylline A 0.22 (72 h) 3.1.1
Dioncophylline C 16.0 (72 h) 3.1.1
Dioncophylline D2 32.0 (72 h) 3.1.1
Dioncophylline F 21.0 (72 h) 3.1.1
Dioncoquinone A 29 (72 h) 58 (72 h) 3.2.1
Dioncoquinone B 11 /72 h) 18 (72 h) 3.2.1
Dioncoquinone C 14 (72 h) 3.2.1
Dioncoquinone D 80 (72 h) 3.2.1
Dioncoquinone E 100 (72 h) 3.2.1
Emodin 37.7 (24 h) x KMS12PE 3.2.1
Epigallocatechin gallate 58.8 (48 h) 28.0 (48 h) 3.2.8
Fangchinolin >30 (24 h) 3.1.1
Formononetin ~75 (72 h) x 3.2.7
Forskolin ~80 (72 h) ~4 (72 h) ~4 (72 h) ~80 (72 h) ~4 (72 h) 3.3.2
Gallic acid 96.8 (48 h) 23.3 (48 h) 3.2.8
Gambogic acid x x ~2.5 (12 h) ~2.8 (8 h) 3.2.7
Genistein 46.76(72 h) x
128.82
(72 h) 3.2.7
Glucomoringin 6.08 (48 h) 3.1.2













Isobavachalcone ~10 (48 h) 3.2.5
Jozimine A2 5.0 (24 h) 3.1.1
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Komaroviquinone MUM24 (0.65, 48 h) 3.3.2
Luteolin x 3.2.6
Lycorine ANBL6, ANBL6BR,ARP1, KMS11 3.1.1
Mangiferin x 3.2.7
Matrine 9059 (24 h)6603 (48 h)
8777 (24 h)




23.2 (24 h) 33.4 (24 h) 25.4 (24 h) 3.3.3
25-O-methylcimigenol-3-




2.6 (72 h) 3.1.1
Miyabenol C 20.8 (24 h) 12.1 (24 h) 3.2.4






















Pentagalloyl glucose 10.24(72 h) 23.92 (72 h)
U266B1 (36.18,
72 h) 3.2.8








KMS11 (0.75, 72 h)





































KM3 (80, 48 h)





β-sesquiphellandrene 5–10(72 h) 5–10 (72 h) 3.3.1
Tannic acid 11.0 (48 h) 12.5 (48 h) 3.2.8
Tanshinone IIA x 3.3.2
Theaflavin digallate ARP1 (0.59, 72 h),KMS11 (0.27, 72 h) 3.2.8
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Thymoquinone 10 (24 h) 10 (48 h) 3.3.4
Ursolic acid ~25 (96 h) 26.56 (24 h) ~25 (96 h) 3.3.3
ε-viniferin 45.7 (24 h) 30.8 (72 h) 3.2.4
Withaferin A 0.17 (72 h) 3.3.3
Withanolide F 0.1 (72 h) 3.3.3
Wogonin 143.2 (24 h) 3.2.6
Table 2. Overview on investigated pathways and regulated molecules. Data collection is restricted to data presented
in figures of the respective study dealing with investigations on myeloma cells only (MMP, mitochondrial membrane
potential). Synergism and inhibition (marked with *) with other drugs are outlined (BTZ/bortezomib, Thal/thalidomide,
Mel/melphalan, Dex/dexamethasone, Dox/doxorubicin, Cyclophos/cyclophosphamide, Pom/pomalidomide). Where
applicable, the testing of the compounds on primary myeloma cells (CD138+ selected and patients’ bone marrow mononu-
clear cells stained for analysis of myeloma cells with CD38++/CD45+/−) is noted. Some compounds were also tested in
tumor models (mostly mice, with one exception using chorioallantoic membrane (CAM) assay). MM-cancer stem cells
(MM-CSC) are rather part of the malignant cells; however, here they are outlined in the section of tumor-microenvironment
(Tumor-ME) to underline the importance of these tumor-initiating cells. Data in this section also includes data obtained



































actein apoptosis AnnV 3.3.3
Alantolactone cell cycle,apoptosis
CDK4,2 cyclin
D1 E2, stroma cells 3.3.1
Ancistrocladisine
















































Bergamottin STAT3 STAT3 3.2.3
Betulinic acid NF-kB, MMP NF-kB, ROS,bcl-2, bax Nude mice 3.3.3
Betulinic acid STAT3 3.3.3
Bigelovin block E2F1 cyclin D, E, A,CDK4 CD138+ 3.3.1
Bruceantin MMP c-myc Scid mice MMP 3.3.3
Bruceantin Migration,Notch Notch MM-CSC 3.3.3
Butein STAT3 bcl-2, SHP,c-Src 3.2.5







BTZ, Thal Athymic nudemice 3.1.2
Cardamonin NF-kB bcl-2, bcl-XL 3.2.5
Celastrol NF-kB, MMP 3.3.3






assay stroma cells 3.3.1
Coleon G Proliferation MM-CSC 3.3.2
Coleon O proliferation MM-CSC 3.3.2
Crocin JAK2/STAT3 SHP-1, blc-2,CXCR4, VEGF 3.3.4
Curcumin STAT1/3 STAT1/3 Dex 3.2.3


















Dihydrocaffeic acid proteasomeactivity ROS, MMP * inhibits BTZ CD138+ 3.2.2



















proliferation BTZ, Thal 3.2.6
Dioncophylline A apoptosis AnnV 3.1.1
Dioncophylline C apoptosis AnnV 3.1.1
Dioncophylline D2 apoptosis AnnV 3.1.1
Dioncophylline F apoptosis AnnV 3.1.1
Dioncoquinone A apoptosis AnnV 3.2.1
Dioncoquinone B apoptosis AnnV 3.2.1
Dioncoquinone C apoptosis AnnV 3.2.1
Dioncoquinone D apoptosis AnnV 3.2.1
Dioncoquinone E apoptosis AnnV 3.2.1
Emodin JAK2/STAT3 Mcl-1, gp130 3.2.1
Epigallocatechin







Formononetin STAT3/5, bcl-2, VEGF,ROS BTZ Nude mice 3.2.7
Forskolin viability bim Dox, Dex, MelBtz, Cyclophos CD138+ 3.3.2





NFkB Osteoclass (murine) 3.2.7
Gambogic acid Hypoxia,PI3K/AKT/mTOR HIF-1a
Balb/c nude
mice 3.2.7
Gambogic acid ROS Sirt1 3.2.7
Genistein NF-kB miRNA-29b 3.2.7
Genistein apoptosis caspase 3 3.2.7
Genistein NF-kB ICAM1, bcl-2,bcl-XL 3.2.7
Glucomoringin NF-kB NF-kB Nude mice 3.1.2
Glucoraphanin NF-kB NF-kB Nude mice 3.1.2
Gossypol apoptosis bcl-2, bcl-XL 3.3.1
Gossypol IL-6 inducedJAK2/STAT3 Mcl-2, bcl-2 3.3.1




bcl-2, PIAS3 BTZ 3.3.1





Isobavachalcone autophagy LC3-II chloroquine,beclin shRNA 3.2.5
Jozimine A2 viability 3.1.1
Komaroviquinone cytotoxicity 3.3.2






BTZ CD138+ MM-CSC 3.1.1
Mangiferin viability 3.2.7































Miyabenol C MMP 3.2.4



















glucose myc inhibition * inhibits BTZ 3.2.8
Plumbagin apoptosis AnnV 3.2.1







Pterostilbene proliferation p-AKT, p-p38,MMP 3.2.4







Resveratrol ROS SMAC 3.2.4








bax BTZ, Thal CD138+ 3.2.4
β-
sesquiphellandrene apoptosis bcl-2 3.3.1
Tannic acid MMP ROS * inhibits BTZ CD138+ 3.2.8











Thymoquinone STAT3, p-AKT bcl-2, bcl-XL Thal, BTZ 3.3.4






























Wogonin p-AKT Bax 3.2.6
3. Results and Discussion
3.1. Alkaloids and Other Heteroaliphatic Compounds
3.1.1. Alkaloids
The first compound class discussed in this review are alkaloids. Alkaloids are well-
known for their cytotoxic effects and are therefore used for the treatment of different
cancers [16]. Most prominent examples are proto-alkaloids, such as the taxane derivatives
paclitaxel and docetaxel, as well as the vinca alkaloids vinblastine, vincristine, vindesine,
and vinorelbine, which belong to the group of indole alkaloids. With regard to multiple
myeloma, the use of taxane derivatives has not been reported; however, vinca alkaloids
have been components of myeloma therapy for a long time until more specific therapies
were developed.
Our literature search revealed that most reports have been made for the group of
isoquinoline alkaloids, with twelve components, and another two compounds of the
phenanthridine type (Figure 1).
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Figure 1. Alkaloids with reported activity against myeloma cell lines. 
Three studies deal with the effect of berberine on myeloma cells applying RPMI8226 
and U266 cell lines with miRNA screening methods [17–19]. Berberine, a well-known iso-
quinoline alkaloid of the protoberberine type, is distributed among the Berberidaceae, Pa-
paveraceae, and Ranunculaceae plant families and mostly isolated from different Berberis 
species [20,21]. Berberine is known for its proapoptotic and autophagic potential against 
many types of cancer but also for its chemosensitizing properties suggesting its use in 
combination therapy [21–23]. With regard to MM, berberine downregulated miRNA-21 
expression and significantly upregulated programmed cell death 4 (PDCD4) leading to 
i re 1. l l i it re rte acti ity against yelo a cel lines.
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Three studies deal with the effect of berberine on myeloma cells applying RPMI8226
and U266 cell lines with miRNA screening methods [17–19]. Berberine, a well-known
isoquinoline alkaloid of the protoberberine type, is distributed among the Berberidaceae,
Papaveraceae, and Ranunculaceae plant families and mostly isolated from different Berberis
species [20,21]. Berberine is known for its proapoptotic and autophagic potential against
many types of cancer but also for its chemosensitizing properties suggesting its use in
combination therapy [21–23]. With regard to MM, berberine downregulated miRNA-21
expression and significantly upregulated programmed cell death 4 (PDCD4) leading to
apoptosis and G2 phase cell cycle arrest in RPMI8226 cells [17]. However, specific apoptosis
was only 8% at a concentration of 75 µM and the IC50 for growth inhibition was 135 µM after
48 h of incubation. Therefore, the main effect is the regulation of miRNA-21 also known
as “oncomir” and as such driving tumor growth. The authors, furthermore, hypothesize
that the suppression of cell growth might (at least partly) result from the modulation of
the IL-6/STAT3 pathway and that the increased expression of PDCD4 might result in the
suppression of the p53 signaling pathway. In the following, Feng et al. systematically
investigated common signaling pathways and found that three miRNA clusters (miR-
99a~125b, miR-17~92, and miR-106~25) were significantly downregulated in MM cells after
treatment with berberine [18]. As the three clusters are linked by TP53, ErbB, and MAPK,
the authors suggest that these signaling pathways might be responsible for the suppression
of cell growth. Additionally, the miR-99a~125b cluster is proposed as a potential target
for the treatment of MM. Gu et al. came to similar results after investigating the miR-
106b/25 cluster in berberine treated MM cells [19]. Here, inhibition of both p38 MAPK
and phopho-p38 MAPK was detected, indicating the miR-106b/25 cluster functioning
as oncogene.
Li et al. isolated several naphtylisoquinoline alkaloids from the Congolese liana An-
cistrocladus ileboensis, which were tested for their apoptotic activity on INA6 cells using
annexin-V-/PI staining and analysis by flow cytometry [24]. Of the isolated compounds,
dioncophylline A, C, D2, and F, as well as 4′-O-demethyldioncophylline A, 4′-O-demethyl-
7-epidioncophylline A, 5′-O-methyldioncophylline D, and ancistrocladisine A showed
activities with EC50 values ranging from 0.22 to 32.0 µM after 72 h of incubation (Table 1).
In the same study, 5′-O-demethyldioncophylline A, a related compound isolated from
Triphyophyllum peltatum was tested showing an EC50 value of 1.5 µM. Except for dionco-
phyllines C and F, all tested compounds showed myeloma cell selectivity as compared
to peripheral blood mononuclear cells (PBMCs). With regard to the structural properties,
naphtyl coupling to position 7 of the isoquinoline ring, as, e.g., for dioncophylline A, is
superior (for both activity and selectivity) than coupling to position 5, as observed for
dioncophyllines C and F. Furthermore, N-methylation, as present in dioncophylline D2,
decreases the activity compared to compounds with secondary amine functions. In contrast,
the configurations of the two vicinal methyl groups seem to have a lesser impact on the
compounds’ activity as well as the methylation pattern of the two distal hydroxyl-groups.
Fangchinoline, a bisbenzylisoquinoline alkaloid was investigated for its activity on
U266 and the chronic myeloid leukemia cell line KBM5 using a variety of assays [Jung et al.,
2019]. Fangchinolin is one of the two major alkaloids of Stephania tetrandra a traditional
remedy in China and other oriental countries [25]. The compound attenuated the growth
of the cell lines and lowered NF-κB as well as AP-1 activation. The authors determined
attenuated phosphorylation of IκB kinase and p65 as possible mechanisms for the effects
and furthermore observed a significant enhancement in TNFα-driven apoptosis.
Another dimeric alkaloid, the naphtylisoquinoline dimer jozimine A2 was isolated
from Ancistrocladus abbreviatus and tested for its effect on MM1S and two other cancer cell
lines using an MTT assay [26]. The IC50 value for MM1S was determined with 5.0 µM after
24 h of incubation.
The second class of alkaloids with reported antimyeloma activity are phenanthridine
type alkaloids, namely lycorine and matrine. First isolated more than one hundred years
ago, lycorine was subject of numerous pharmacological studies showing low toxicity
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and at the same time high potency against various cancer cell lines [27]. Therefore, the
chemical structure of lycorine was used as natural lead for further drug development.
Wang et al. investigated the effect of lycorine on myeloma cell lines ARP1, KMS11, ANBL6,
and ANBL6 and found that the compound inhibited proliferation by decreasing ALDH1+
cells, which are supposed to be cancer stem cells [28]. Furthermore, lycorine was found
to act via the Wnt/β-catenin pathway by lowering β-catenin protein levels and to exhibit
synergistic effects when combined with bortezomib. Additional synergisms were described
for combinations with pomalidomide, doxorubicin, and the alkylating agent melphalan,
though the latter combination showed less pronounced effects. These results were as well
observed in bortezomib resistant cells, indicating the compound’s potential to overcome
bortezomib resistance and thus displaying a promising agent for MM treatment, either
alone or in combination with other chemotherapeutics. In this study, lycorine was used up
to a concentration of 5 µM.
The second phenanthridine type alkaloid is matrine, a bioactive ingredient of Sophora
flavescens and Sophora tonkinensis, two medicinally used plant species in China and many
Eastern countries [29–31]. The compound was found to possess a variety of pharmacologi-
cal activities comprising different types of cancer [29–32]. Same as lycorine, also matrine
was used as natural lead compound, also because it is very stable and shows only a few
functional groups; therefore, it can be easily modified [31,32]. Investigations on the an-
timyeloma potential of matrine were conducted with RPMI8226 and U266 cell lines as well
as bone marrow mononuclear cells using MTT assays [33]. Additionally, apoptotic cells
were studied by Hoechst 33258 staining and flow cytometry and different mechanisms were
evaluated by Western blotting. Activation of caspase-3 and poly (ADP-ribose) polymerase,
upregulation of Bim expression and downregulation of bcl-2 and survivin expression, as
well as inhibition of phosphorylated AKT were identified as responsible mechanisms for
the observed effects. However, with IC50 values in the millimolar range, the therapeutic
potential of the drug must be questioned.
3.1.2. Other Heteroaliphatic Compounds
This section describes four compounds, which contain the heteroatoms nitrogen
and/or sulfur within their structure (Figure 2).
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pression of STAT3-regulated gene products and induced the accumulation of cells in 
G1phase. As the downregulation of STAT3 could be reversed by pervanadate, an inducer 
of cellular tyrosine phosphorylation, the authors suggest an involvement of a protein ty-
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in combination with bortezomib and thalidomide. Finally, capsaicin was administered i.p. 
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e first co poun is capsaicin, the pungent principle of chili pepper [34,35]. The
co po n belongs to the capsaicinoids, a compound class sometimes inclu ed within
the alkaloid family [34]. However, as these compounds neither show a cyclic nitrogen
nor basicity (the nitrogen is an amide and thus neutral), the compound does not fulfil the
criteria for an alkaloid. Capsaicin has been repeatedly studied for its anticancer activity
with most reports dealing with cancers of the liver and the intestine [36–38]. With regard
to its effect on myeloma cells, the compound was found to inhibit constitutive and IL-6
induced STAT3 activation as well as activation of JAK 1 and c-Src [39]. Only little effects on
STAT5 and no effect on ERK 1/2 were observed. Furthermore, capsaicin downregulated
the expression of STAT3-regulated gene products and induced the accumulation of cells in
G1phase. As the downregulation of STAT3 could be reversed by pervanadate, an inducer of
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cellular tyrosine phosphorylation, the authors suggest an involvement of a protein tyrosine
phosphatase. Additional experiments revealed antiproliferative activity against MM1S and
U266 cells and induction of apoptosis, with a potentiating effect of capsaicin in combination
with bortezomib and thalidomide. Finally, capsaicin was administered i.p. to athymic mice,
demonstrating inhibition of myeloma tumor growth also in vivo.
Brunelli et al. studied glucoraphanin and glucomoringin, two glucosinolates present
in species of the Brassicaceae family, on various cancer cell lines [40]. RPMI8226 cells were
used to study antiproliferative effects resulting in IC50 values of 7.7 and 6.9 µM, respectively,
after 48 h of incubation. Both compounds inhibited NF-κB activity and induced apoptosis,
with stronger effects observed for glucomoringin. Antimyeloma activity of glucomoringin
was also observed in a SCID-mouse model, however, toxicity was discussed at prolonged
(3 week) treatment.
Diallyl trisulfide is an organosulfur compound derived from garlic, a natural product
that has been ethnomedicinally used in China for more than a thousand years [41,42].
It is one of the decomposition products of allicin, that rapidly occurs (besides diallyl
sulfide and diallyl disulfide) after cutting or squeezing the fresh cloves [41,43]. Diallyl
trisulfide was investigated on RPMI8226 and H929 cells using MTT assay, resulting in high
micromolar IC50 values [42]. Further experiments were performed investigating the effects
on the myeloma stem cell fraction defined as side population using Hoechst staining. The
compound reduced the survival rate, blocked colony formation, induced cell cycle arrest
and promoted apoptosis of SP cells to an extent comparable to bortezomib treatment.
Interestingly, all compounds of this subsection are food ingredients, meaning that
depending on one’s preference for vegetables or spices, they are consumed on a regular
basis. With three of the four components showing apoptotic activity and antiproliferative
effects at low micromolar concentrations, they might well play a role in cancer chemopre-
vention provided that they are bioavailable and do not undergo rapid cooking degradation
or metabolic elimination. Thermal decomposition particularly accounts for glucosinolates,
which are significantly degraded upon boiling [44]. Thus, either non-thermal processing
of cruciferous vegetables or their use as fresh or raw extracts is proposed to benefit from
their effects [44,45]. Capsaicin, in contrast, does not suffer from thermal degradation but
displays only low oral bioavailability as it is rapidly metabolized in the liver [34]. Therefore,
current research focusses on the use of nanoparticles or other delivery systems in order to
increase its therapeutic potential [35,36].
3.2. Phenolics
3.2.1. Quinones
This section contains one anthraquinone, namely emodin, and six naphthoquinones
(Figure 3).
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JAK2/STAT3 pathway and downregulation of Mcl-1 suggests a good potential as anti-
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triggered activation of caspase-3 and caspase-9 without affecting the expression of other
bcl-2 family members except Mcl-1. According to the authors, the selective inhibition
of the JAK2/STAT3 pathway and downregulation of Mcl-1 suggests a good potential as
anti-myeloma reagent. However, in a recent report of the European Food Safety Authority
(EFSA), the compound (together with other hydroxyanthracene derivatives) was found to
produce genotoxic effects in vitro and to increase the risk of colorectal cancer [48]. Though
the genotoxic effect of emodin was only observed in vitro, Aloe extracts containing emodin
were also found genotoxic in vivo. Based on these findings, the European Commission pro-
posed to prohibit the use of hydroxyanthracene derivatives, and all preparations containing
them, in food [49].
Bringmann et al. isolated dioncoquinones A and B from callus culture of the tropical
liana Triphyophyllum peltatum [50]. Both compounds were measured for their apoptotic
potential using INA6 and RPMI8226 cell lines, with EC50 values of 59 and 78 µM (dion-
coquinone A) as well as 11 and 18 µM (dioncoquinone B), respectively. Both compounds
did not affect healthy PBMCs. In a follow-up study, three more naphthoquinone deriva-
tives (dioncoquinones C-E) were isolated and another already known natural product
(plumbagin) was yielded by organic synthesis [51]. Dioncoquinone C showed similar
activity against the viability of INA6 cells with an EC50 of 14 µM, whereas dioncoquinones
D and E were less effective, with values of 80 and 100 µM, respectively. However, PBMCs
were not affected by any of the three compounds. Plumbagin, instead, showed much
higher inhibitory activity, with an EC50 of 0.8 µM, but also affected healthy PBMCs to the
same extent. Comparison of dioncoquinone structures showed that the highest activity is
achieved with free hydroxyl groups in position 3 and 6, as present in dioncoquinones B and
C. Comparison with dioncophyllines isolated from the same plant species and also from
Ancistrocladus ileboensis, revealed that dioncoquinones did not reach the activities of their
alkaloid counterparts (see Section 3.1.1). Of the group of naphthoquinones, plumbagin
was subjected to various studies confirming its anticancer effects and suggesting its further
development as antineoplastic drug [52,53]. However, with regard to MM, the apoptotic
effects of plumbagin were equally pronounced against healthy PBMCs.
3.2.2. Phenylethanoids and Phenylpropanoids
This section contains one phenylethanoid, namely oleacein, two simple phenyl-
propanoids, and two condensed phenylpropanoids, also known as lignans (Figure 4).
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Oleacein, a phenylethanoid ester of hydroxytyrosol with a secoiridoidic acid, is one 
of several active polyphenols found in olive oil [54]. The compound was tested for its 
effect on cell viability against eight different human myeloma cell lines and showed IC50 
values in the range of 5 to 20 µM (Table 1). Viability was reduced even in the presence of 
bone marrow stromal cells, while healthy PBMCs were not affected. Accumulation of both 
acetylated histones and α-tubulin as well as the downregulation of several histone 
deacetylases were identified as mechanism of action. Oleacein, moreover, showed syner-
gistic effects with carfilzomib, a proteasome inhibitor, indicating a potential use for com-
bination therapy. 
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the range of 5 to 20 µM (Table 1). Viability was reduced even in the presence of bone marrow
stromal cells, while healthy PB Cs were not affected. Accumulation of both acetylated
histones and α-tubulin as well as the downregulation of several histone deacetylases were
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identified as mechanism of action. Oleacein, moreover, showed synergistic effects with
carfilzomib, a proteasome inhibitor, indicating a potential use for combination therapy.
Dihydrocaffeic acid is one of the simplest phenylpropanoids and (together with other
hydroxycinnamic acids) a substructure of numerous natural products. The compound
itself was investigated (together with several other polyphenols) on U266 and RPMI8226
cell lines showing IC50 values of 61.9 and 344.0 µM, respectively [55]. However, the more
interesting finding in this report was the detection of chemical interactions between some
compounds with bortezomib. These interactions were only found for structures with
vicinal aromatic hydroxyl groups that directly reacted with the boronic acid moiety of
bortezomib thus antagonizing the effect of the proteasome inhibitor.
In two studies, the antimyeloma effect of 1′-acetoxychavicol acetate, a component
of the ethnobotanically used plant species Alpinia galanga, was investigated [56,57]. The
first study found that the compound acted via the NF-κB pathway, decreasing the nuclear
location of NF-κB but increasing the accumulation of cytosolic NF-κB in RPMI8226 cells [56].
1′-acetoxychavicol acetate also induced cleavage and thus activation of caspases 3, 8, and
9 and inhibited serine phosphorylation as well as degradation of IκBα. The effect was
also studied in vivo, where treatment of NOD/SCID mice with 1′-acetoxychavicol acetate
significantly decreased tumor growth. A follow-up study by the same group revealed
that the compound upregulates the expression of both TNF-related apoptosis-inducing
ligand/Apo2 ligand (TRAIL/Apo2L) and TRAIL receptor death receptor 5 (DR5) [57]. A
third study investigated several analogues of 1′-acetoxychavicol acetate and found a more
potent agent (TM-233) [58]. Thereby, the ethenyl feature of 1′-acetoxychavicol acetate was
replaced by a 9-anthryl moiety, leading to increased induction of apoptosis compared to its
parent compound.
Honokiol a lignan biphenol present in traditionally used Magnolia species was found
to exhibit anticancer activity on various types of cancer, thereby modulating multiple
oncogenetic targets [59,60]. The compound was, furthermore, found to enhance the an-
tineoplastic effect of several chemotherapeutic agents, e.g., doxorubicin and paclitaxel,
in combination treatment [61]. The effects of honokiol were also investigated in U266
myeloma cells [62]. Similar to the simple phenylpropanoid 1′-acetoxychavicol acetate,
the dimeric phenylpropanoid was found to suppress NF-κB activation and to block TNF-
induced phosphorylation, ubiquination, and degradation of IκBα. An in vivo mouse model
confirmed the downregulation of NF-κB.
The last compound of this section, arctiin, is a classical lignan, where the two phenyl-
propane units are linked by the central carbons of their side chains [63]. It was first
identified in Arctium lappa, a popular medicinal herb and health supplement for the anti-
influenza treatment in East Asia [64]. Arctiin was investigated for its effect on MM1S,
RPMI8226, and U266 cells. The authors describe effects in U266 cells, the only cell line
with constitutive activation of STAT3, with an IC50 value below 20 µM after 24 h of incuba-
tion [65]. Further experiments revealed that arctiin abrogated the constitutive activation
of Scr phosphorylation as well as JAKs 1 and 2. The compound, furthermore, enhanced
mRNA and protein levels of protein tyrosine phosphatase ε (PTPε). However, usage of
complete medium instead of starving medium abrogated the effects. Additionally, arctiin
treatment failed to block IL-6 induced STAT3 phosphorylation in RPMI8226 and MM1S
cells. The targeting of different pathways by honokiol compared to arctiin might be ex-
plained by their different geometries. Arctiin belongs to the dibenzylbutyrolacton type
lignans and contains two stereocenters in the lactone ring, as well as a β-oriented glucose
moiety, resulting in an almost ring-shaped geometry. Honokiol, in contrast, shows an
S-form and, moreover, much lower polarity.
3.2.3. Diarylheptanoids and Pyrones
This section deals with the diarylheptanoid curcumin and with one α- and two γ-
pyrones (Figure 5).
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phorylation of STAT5 was not affected. Additionally, the compound affected dexame-
thasone-resistant MM1R cells. In a more recent study, curcumin was compared to β-ses-
quiphellandrene (see Section 3.3.1), revealing IC50 values below 25 µM (U266) and 10 µM 
(MM1S) after 72 h of incubation [71]. Curcumin was also part of a clinical trial 
(NCT00113841) evaluating the clinical tolerance and safety of the compound in myeloma 
patients in a pilot study, thereby measuring the change of NF-kB protein expression in 
PBMCs. However, a consecutive phase II study (NCT01269203) on the reduction of symp-
toms during the treatment with lenalidomide was withdrawn.  
Bergamottin is a constituent of grapefruit juice and the only natural α-pyrone with 
reported antimyeloma activity, though its compound class is more commonly referred to 
as coumarin or furanocoumarin [72]. Bergamottin was found to be antineoplastic in dif-
ferent tumor models and also showed acceptable bioavailability [73]. In MM cells, the 
compound was found to abrogate constitutive STAT3 activation through inhibition of 
phosphorylation of JAK 1 and 2 as well as c-Src. Bergamottin, moreover, induced the ex-
pression of tyrosine phosphatase SHP-1, downregulated the expression of STAT3-regu-
lated gene products, and significantly potentiated the apoptotic effects of bortezomib and 
thalidomide in U266 myeloma cells. 
Capillarisin, a constituent of Artemisia capillaris, was also found to inhibit constitutive 
and inducible STAT3 activation through activation of upstream JAK 1 and 2 and c-Src 
[74]. Likewise, the potentiation of the apoptotic effect of bortezomib was also observed for 
capillarisin. However, with an IC50 of 200 µM (after 36 h of incubation) the compound 
does not seem promising for therapeutic use.  
Though displaying three different chemical structures, all three compounds in this 
section act via inhibition of the STAT3 (and STAT1) pathway. Similar to the group of het-
eroaliphatic compounds, also here two components are likely to be consumed regularly, 
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used spice and coloring food additive [66]. It is one of the most investigated natural
products with regard to anticancer activity knowing to regulate miRNA expression and
modifying a series of signaling pathways in various types of cancer (e.g., endometrial
cancer or human glioblastoma) [67–69]. With regard to MM, curcumin has been inves-
tigated for its effect on U266, MM1S, MM1R, and RPMI8226 cell lines and completely
suppressed cell proliferation at a concentration of 10 µM [70]. Curcumin was found to
inhibit IFNα-induced STAT1 phosphorylation and IL-6 induced STAT3 phosphorylation,
whereas phosphorylation of STAT5 was not affected. Additionally, the compound affected
dexamethasone-resistant MM1R cells. In a more recent study, curcumin was compared to
β-sesquiphellandrene (see Section 3.3.1), revealing IC50 values below 25 µM (U266) and
10 µM (MM1S) after 72 h of incubation [71]. Curcumin was also part of a clinical trial
(NCT00113841) evaluating the clinical tolerance and safety of the compound in myeloma
patients in a pilot study, thereby measuring the change of NF-kB protein expression in
PBMCs. However, a consecutive phase II study (NCT01269203) on the reduction of symp-
toms during the treatment with lenalidomide was withdrawn.
Bergamottin is a constituent of grapefruit juice and the only natural α-pyrone with
reported antimyeloma activity, though its compound class is more commonly referred to as
coumarin or furanocoumarin [72]. Bergamottin was found to be antineoplastic in different
tumor models and also showed acceptable bioavailability [73]. In MM cells, the compound
was found to abrogate constitutive STAT3 activation through inhibition of phosphorylation
of JAK 1 and 2 as well as c-Src. Bergamottin, moreover, induced the expression of tyrosine
phosphatase SHP-1, downregulated the expression of STAT3-regulated gene products,
and significantly potentiated the apoptotic effects of bortezomib and thalidomide in U266
myeloma cells.
Capillarisin, a constituent of Artemisia capillaris, was also found to inhibit constitutive
and inducible STAT3 activation through activation of upstream JAK 1 and 2 and c-Src [74].
Likewise, the potentiation of the apoptotic effect of bortezomib was also observed for
capillarisin. However, with an IC50 of 200 µM (after 36 h of incubation) the compound
does not seem promising for therapeutic use.
Though displaying three different chemical structures, all three compounds in this
section act via inhibition of the STAT3 (and STAT1) pathway. Similar to the group of
heteroaliphatic compounds, also here two components are likely to be consumed regularly,
given a favor for spicy food or grapefruit juice, respectively.
3.2.4. Stilbenoids
This section discusses resveratrol, one of the most investigated natural products
against multiple myeloma, and three of its derivatives, includin one dimeric and one
trimeric stilbenoid (Figure 6).
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Similar to curcumin, resveratrol is an anticancer compound of major interest and
known to act via an array of different pathways [75]. It, moreover, shows immunomodula-
tory effects in the tumor microenvironment and has chemosensitizing properties, suggest-
ing its potential use in therapy-refractory cancer [76,77]. Several studies investigated the
antimyeloma properties of resveratrol [78–83], a compound present in red wine and linked
to its health beneficial effects [84]. Boissy et al. investigated the effect of resveratrol on the
growth of RPMI8226 and OPM2 myeloma cells and found induction of apoptosis [78]. In
addition, they investigated the effect of resveratrol on cells of the tumor microenvironment.
Thus, they show that the compound inhibited NF-κB ligand (RANKL)-induced formation
of osteoclasts from primary monocytes. Furthermore, resveratrol promoted the expres-
sion of osteocalcin and osteopontin in human bone marrow mesenchymal stem cells and
stimulated their response to 1,25(OH)2 vitamin D3. Together with the up-regulation of
1,25(OH)2 vitamin D3 receptor expression, resveratrol thus prevented osteoclast formation
and promoted osteoblast differentiation. Sun et al., furthermore, revealed that resveratrol
downregulated the expression of anti-apoptotic proteins (bcl-2, bcl-xL, and XIAP) and
upregulated the expression of the proapoptotic protein Bax [79]. In addition, resveratrol
inhibited the constitutive expression of matrix metalloproteinases MMP-2 and MMP-9 and
suppressed their function in MM cells. MTT assays revealed inhibition of cell proliferation
with IC50 values of 72, 74, and 80 µM against RPMI8226, U266, and KM3 cells, respectively,
after 48 h of incubation. Invasion assays using the same cell lines resulted in IC50 values of
64, 93, and 153 µM, respectively. Bhardwaj et al. showed that resveratrol not only interfered
with the NF-κB pathway, but also inhibited the constitutive and IL-6 induced activation
of STAT3 [80]. The authors, moreover, discovered that resveratrol potentiated the anti-
apoptotic activity of bortezomib and thalidomide. Li et al. evaluated synergistic effects of
resveratrol with carfilzomib and found the combination to inhibit cell growth by promoting
oxidative stress in MM cells [81]. In the last study, resveratrol was investigated for its effect
on the overexpression of NEAT1 in U266 and LP1 cells [82]. NEAT is a long non-coding
RNA found to promote ß-catenin expression and unfolded protein response (UPR), an
essential survival mechanism for myeloma cells. The authors identified the overexpression
of this RNA in a screen on patient tissues and found it also highly expressed in myeloma
cell lines. Resveratrol reversed the effect of NEAT1 overexpression on MM cells through
the Wnt/β-catenin signaling pathway and thus counteracted proliferation, migration, and
invasion of MM cells. IC50 values for the two investigated cell lines were determined with
40.7 (LP1) and 33.7 µM (U266), respectively, after 72 h of incubation.
Barjot et al. investigated the antiproliferative and antiapoptotic effects of two naturally
occurring resveratrol oligomers, namely ε-viniferol and miyabenol C, on RPMI8226 and
U266 cell lines [83]. The oligomer ε-viniferol showed higher IC50 values on RPMI8226 than
the resveratrol monomer (45.7 vs. 26.3 µM) and not statistically different IC50 values for
U266 cells (30–40 µM). The trimer miyabenol C, however, was found to be more effective,
with IC50 values of 20.8 and 12.1 µM, respectively. The latter compound was also the
most effective in inducing cell death. All three components revealed potential to activate
caspases and were associated with disruption of the mitochondrial membrane potential.
Pterostilbene (or 3′,5′-dimethoxyresveratrol) is a compound found in blueberries and
grapes [85]. Pterostilbene was investigated on H929 and bortezomib-resistant H929R cell
lines, showing IC50 values of 22.83 and 34.80 µM, respectively, after 48 h of incubation.
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Mechanistically, the compound was found to cause apoptosis via a caspase-dependent
pathway as well as through downregulation of p-AKT and activation of the MAPK signal-
ing pathways. Pterostilbene, moreover, showed synergistic effects with histone deacetylase
inhibitors panobinostat and vorinostat. Xie et al. investigated pterostilbene on additional
cell lines ARP1, OCIMY5, and RPMI8226 with comparable IC50 values [86]. The compound
caused cell cycle arrest at G0/G1 phase by enhancing ROS generation and reducing mi-
tochondrial membrane potential (MMP). The authors thereupon hypothesized that the
anti-tumor effect may be caused by the activation of the extracellular regulated protein
kinases (ERK) 1/2 and c-Jun N-terminal kinase (JNK). The anti-myeloma effect of pterostil-
bene was also demonstrated in a mouse model, where the compound provoked a reduction
of tumor volume after intraperitoneal injection. Reduction of tumor size in mouse models
was, moreover, observed for DCZ0801, a semi-synthetic derivative obtained through fusion
of pterostilbene with oxophenamide [87,88]. In the latter study, the analogue was found to
suppress glycolysis via inactivation of the AKT/mTOR pathway [88].
The extensive studies on resveratrol (in contrast to many other compounds) revealed
various mechanisms of actions, which were partly confirmed for its derivatives. Although
the reported IC50 values of the above-described compounds do not suggest further pro-
motion as potential chemotherapeutics, resveratrol was still evaluated in a phase II study
for its safety and tolerability (NCT00920556). However, the study was terminated early
due to minimal efficacy signals observed. Due to their anticancer properties and their
presence in fruits, stilbenoids have attracted the interest of food industry promoting their
health-beneficial effects [89,90]. With regard to their bioavailability, resveratrol is known
to be rapidly degraded in the liver, but several of its metabolites show protective effects
against cancer [91]. Less is known about its oligomers, which also raises the demand for
proper toxicological evaluation of these compounds for their use in food industry [90].
Pterostilbene, in contrast, was found pharmacologically safe showing no organ-specific or
systemic toxicity [92]. In addition, the compound is more lipophilic than resveratrol show-
ing higher intestinal permeability and metabolic stability [93]. The higher bioavailability
and the fewer adverse effects compared to resveratrol suggest pterostilbene as promising
chemopreventive nutritional supplement [93,94].
3.2.5. Chalcones
Four chalcones will be reported in this section, which all show very close structural
relations (Figure 7).
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h s verniciflua [95]. Butein shows several pharmacological pro erties, such as antioxidant,
antihypertensive, anti-inflammatory, and anticancer activity [96,97]. The latter effects were
found to result from the induction of apoptosis, cell cycle arrest, and the regulation of
NF-κB related gene products [97]. In myeloma cells, the compound inhibited proliferation
of U266 and MM1S cells with IC50 values of around 10 and 30–40 µM, respectively, after
72 h of incubation and inhibited both constitutive and IL-6 induced STAT3 activation [95].
The suppression was mediated through the inhibition of activation of JAK 1 and 2 as
well as the upstream kinases c-Src. Butein, moreover, induced the expression of the
tyrosine phosphatase SHP-1 and downregulated the expression of STAT3-regulated genes.
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Additionally, the compound showed synergistic apoptotic effects with both bortezomib
and thalidomide. Interestingly, the vicinal aromatic hydroxyl groups of butein did not
seem to antagonize the effect of bortezomib as was reported for several polyphenols [55],
even though both compounds were applied together.
Cardamonin (2′,4′-dihydroxy-6′-methoxychalcone) is present in the traditional Chi-
nese medicinal plant Alpinia katsumadae, which is meanwhile classified as Alpinia haianensis,
and known to display anticancer properties via modulation of multiple signaling pathways,
such as mTOR, NF-κB, AKT, STAT3, Wnt/β-catenin, and COX-2 [98,99]. The compound
is lacking the two hydroxyl groups in ring B and shows an additional methoxy group
in ring A instead, making it more lipophilic than butein. Cardamonin was tested for its
antiproliferative effect on RPMI8226 and U266 showing IC50 values of approximately 60
and 45 µM, respectively, after 24 h of incubation as well as values of 10 and 15 µM after
48 h of incubation [98]. The apoptotic potential of the compound was determined with an
EC50 of 50 µM after an incubation period of 24 h. Thereby, cardamonin activated caspase-3
and PARP and suppressed the expression of anti-apoptotic proteins of the bcl-2 family. Car-
damonin, furthermore, inhibited NF-κB through suppression of IKK expression and IκBα
phosphorylation and downregulated the expression of NF-κB-regulated gene products.
Isobavachalcone is a compound present in the seeds of Psoralea corylifolia, a traditional
Chinese remedy [100]. The compound is of even lower polarity than the two before
mentioned compounds showing a logP value of approximately 4 (and thus twice the
value of butein), which mostly results from the prenyl moiety. Isobavachalcone showed
antiproliferative effects against H929 cells with an IC50 value of approximately 10 µM
after 48 h of incubation. The compound induced apoptosis but concomitantly enhanced
protective upregulation of autophagy. Consequently, combined treatment with autophagy-
inhibitors such as chloroquine enhanced cell death.
2,4-dihydroxy-3′-methoxy-4′-ethoxychalcone, a compound present in the traditional
medicinal herb Caragana pruinosa, was investigated for its antiproliferative effect on
RPMI8226, MM1S, and U266 cells [101]. With IC50 values of 26.0, 18.4, and 15.0 µM,
respectively, after 24 h of incubation, the compound seems to be the most potent among
the investigated chalcones. With regard to the involved mechanism, 2,4-dihydroxy-3′-
methoxy-4′-ethoxychalcone was found to induce apoptosis via activation of caspases
3 and 9, upregulation of Bad and downregulation of bcl-2 and the survival pathway
PI3K/AKT/mTOR.
Though the four chalcones discussed in this section showed varying polarities, their
antiproliferative potential does not seem to differ significantly. It is also comparable to the
potential of the before discussed stilbenoids, as is their mechanism of action. However, in
contrast to the stilbenoids, the chalcones presented in this review were all isolated from
traditionally used medicinal plants rather than from fruits.
3.2.6. Flavonoids
This section describes nine flavonoids, of which one is a flavanone, five are flavones
and three are of the flavonol-type (Figure 8).
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pigenin is one of the most abundant flavonoids in plant kingdom and therefore
has been the target of various investigations for its use as anticancer agent and for its
role in cancer prevention [102–104]. In these studies, the compound showed anticancer
potential via induction of apoptosis and cell cycle arrest as well as the downregulation
of matrix metalloproteinases and interaction with miRNAs. However, apigenin was also
found to undergo rapid elimination, thus raising the need for, e.g., nanoformulations to
increase its bioavailability [104]. The compound has been studied for its effect on U266
and RPMI8226 cell lines and primary MM cells, where it inhibited proliferation (without
affecting healthy PBMCs), influenced cell cycle progression and induced programmed cell
death [105]. Apigenin thereby blocked CK2 activity, leading to inactivation of multiple
kinases such as the constitutive and inducible STAT3, AKT, ERK, and NF-κB as well as their
upstream kinase partners. Treatment with apigenin also downregulated the expression of
the antiapoptotic proteins Mcl-1, bcl-2, bcl-xL, XIAP, and survivin. Although the study on
the ubiquitin-proteasome pathway by Wu and Fang was performed on solid cancer cell
lines, the described effect on different catalytic activities of the proteasome (chymotrypsin-
/trypsin-like) ight as ell play a role in multiple myeloma [106].
aringenin is the 2,3-dihydro derivative of apigenin and thus belongs to the class of
flavanones, hich possess at least one stereocenter. However, in the case of naringenin
race ization occurs in aqueous solutions [107]. Same as apigenin, naringenin showed
anticancer activity via different mechanisms of action and additionally exhibited protec-
tive effects against natural and chemical toxic agents [108]. Additionally, for naringenin
bioavailability is a major issue, which has been evaluated in several clinical trials [109].
Willer et al. isolated the compound from damiana (Turnera diffusa), a natural aphrodisiac
used in Latin America [110]. Naringenin was investigated against H929 and U266 cells,
showing significant cytotoxic effects at concentrations >25 µM in MM cells compared to
healthy PBMCs. In the same study, apigenin 7-O-(4′′-O-p-E-coumaroyl)-glucoside, a more
complex apigenin derivative, was investigated. The compound, however, exhibited lower
effects on both cancerous and healthy cells and was less selective for myeloma cells.
Luteolin, sa e as apigenin, is of high abundance in the plant kingdom and often shows
co-occurrence. Likewise, it exhibits anticancer effects via different signaling pathways
and against various cancer types, with the most promising results found in pancreatic
and breast cancer models [111–113]. With regard to its anti yelo a activity, the only
report found in literature as in the Chinese language [114]. However, from the English
language abstract it could be deduced that the compound inhibited proliferation and
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caused apoptosis and autophagy in RPMI8226 cells. Luteolin was, furthermore, part of
the abovementioned study on the ubiquitin-proteasome pathway showing comparable
effects to apigenin [106]. The effect of luteolin on myeloma cells was confirmed in a recent
study of our own group, where it showed even higher rates of cell-death induction than
apigenin [115].
Wogonin, one of the major constituents of Scutellaria baicalensis, was investigated on
RPMI8226 cells, showing apoptotic effects with decreased levels of anti-apoptotic bcl-2
protein and significantly increased levels of pro-apoptotic Bax protein [116]. Wogonin
decreased phosphorylation of AKT at Ser473 and thus suppressed its activity. Moreover,
the compound was found to fit well within the AKT1 ligand binding domain by molecular
docking studies. Though the authors propose wogonin as a potential therapeutic agent, an
IC50 value of 143.2 µM (after 24 h of incubation) does not corroborate this suggestion. How-
ever, since MM cells express AKT1 and AKT2 with the latter being even more important,
the isoform selectivity of wogonin could explain the high IC50 values in this cell type.
Another compound present in Scutellaria baicalensis, but also in Oroxylum indicum,
is baicalein [117,118]. Same as the abovementioned flavonoids, baicalein was found to
be active against a variety of cancer cells and thereby acted via different pathways [119],
however, also with limited oral bioavailability [120]. With regard to MM, baicalein was
studied for its effect on U266 cells and showed an IC50 value of 60 µM after 24 h of incuba-
tion [121]. The compound was found to act via a cereblon-dependent down-regulation of
the lymphoid transcription factors IKZF1 and IKFZ3. Cereblon is the primary target for
the immunomodulatory drugs commonly used in myeloma therapy; thus, combination
therapies could be promising and might ameliorate the low apoptotic potential observed
when used as single agent.
Quercetin is another highly abundant flavonoid in plant kingdom and the flavonol
counterpart to luteolin, also displaying vicinal hydroxyl groups in ring B. This structural
feature was one of the key findings of a study on polyphenols (see Section 3.2.2), where
quercetin among other compounds was found to chemically interact with the boronic acid
substructure of bortezomib [55]. IC50 values of quercetin against U266 and RPMI8226 cell
lines were determined with 50.5 and 120.5 µM after 48 h of incubation. While no signaling
pathways were investigated in this study, quercetin, same as other flavonoids, modulated
a number of different pathways in other cancer models [122]. However, in prostate cancer,
Bax detachment from bcl-xL and stimulation of caspases was the most appreciated route,
and a combination with a TNF-related apoptosis-inducing ligand has been recommended
to overcome resistance to apoptosis [123].
Icaritin is a prenylated flavonol from the ethnomedicinally used genus Epimedium and
is currently tested in a phase III clinical trial for advanced hepatocellular carcinoma [124].
The compound also showed promising results in several hematological malignancies [125].
With regard to MM, icaritin was studied for its antiproliferative effect on U266 cell line
with IC50 values of 36.6, 10.1, and 8.6 µM after 24, 48, and 72 h of incubation without
affecting normal hematopoiesis [126]. Acting mainly via inhibition of IL-6/JAK2/STAT3
signaling, icaritin also showed in vivo activity in a xenograft mouse model suppressing
tumor growth.
5,3′-dihydroxy-3,6,7,8,4′-pentamethoxyflavone is one of the components of Gardenia
obtusifolia, a traditional Thai panacea [127]. The compound was investigated on various
cancer cell lines including three human myeloma cell lines (U266, RPMI8226, and MM1S).
Thereby, 5,3′-dihydroxy-3,6,7,8,4′-pentamethoxyflavone inhibited the proliferation of can-
cer cells to a concentration of 1 µM, however, after approximately 96 h of incubation. The
compound was found to act through modulation of AKT-GSK3β pathways and induction
of cyclin-dependent kinase (CDK) inhibitors. In a follow-up study, 5,3′-dihydroxy-3,6,7,8,4′-
pentamethoxyflavone inhibited both constitutive and IL-6 inducible STAT3 activation in
myeloma cells, leading to the suppression of proteins involved in proliferation, survival,
and angiogenesis [128]. Additionally, the apoptotic effects of thalidomide and bortezomib
were significantly potentiated by 5,3′-dihydroxy-3,6,7,8,4′-pentamethoxyflavone.
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Flavonoids are widely distributed in plant kingdom fulfilling important roles in the
plants’ physiological processes [129]. Due to their high abundance and the ready availability
of the major flavonoids, they belong to the most studied compound subclasses. However,
neither the major flavonoids (apigenin, luteolin, and quercetin) nor the more specific
compounds discussed in this section exhibited remarkable antiproliferative effects. Here,
icaritin was the most promising constituent showing an IC50 value in the low micromolar
range and, furthermore, suppressing tumor growth in vivo.
3.2.7. Isoflavones and Xanthones
This section describes two well-known isoflavones, namely genistein and formononetin,
as well as three xanthone derivatives (Figure 9).
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termined IC50 values of 46.7 and 128.8 µM, respectively, after 72 h of incubation [130]. 
Genistein enhanced cleavage and thus activation of caspases 3, 7, and 9, cleavage of PARP 
as well as downregulation of bcl-2 family members. He et al. studied the compound’s 
effect on RPMI8226 cells and found that NF-κB was downregulated and nuclear retention 
of p65 was prevented [136]. Genistein, moreover, downregulated the expression of NF-κB 
related gene products and suppressed constitutive AKT phosphorylation. The suppres-
sion of NF-κB and the modulation of caspase 3 activity of genistein were also observed by 
Xie et al., who studied its effect on U266 cells [131]. The authors, furthermore, revealed 
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as species of the genus Sophora [130,131]. It has been subject of numerous investigations
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been investigated in t o clinical trials, ith pro ising results [135]. Li et al. investigated
the antimyeloma effect of genistein on the proliferation of OPM2 and U266 cells and
determined IC50 values of 46.7 and 128.8 µM, respectively, after 72 h of incubation [130].
Genistein enhanced cleavage and thus activation of caspases 3, 7, and 9, cleavage of PARP
as well as downregulation of bcl-2 family members. He et al. studied the compound’s
effect on RPMI8226 cells and found that NF-κB was downregulated and nuclear retention
of p65 was prevented [136]. Genistein, moreover, downregulated the expression of NF-κB
related gene products and suppressed constitutive AKT phosphorylation. The suppression
of NF-κB and the modulation of caspase 3 activity of genistein were also observed by
Xie et al., who studied its effect on U266 cells [131]. The authors, furthermore, revealed
that the downregulation of NF-κB resulted from up-regulation of micro-RNA 29b.
Formononetin, another well-known isoflavone present in Astragalus membranaceus,
Trifolium pratense, Glycyrrhiza glabra, and Pueraria lobata, was investigated on U266 and
RPMI8226 cell lines [137]. The compound suppressed constitutive STAT3 and STAT5 as
well as upstream kinases JAK1/2 and c-Src via an increased production of reactive oxygen
species (ROS). Formononetin, moreover, downregulated the expression of STAT3-regulated
anti-apoptotic, angiogenic, and proliferative gene products, which correlated with the
induction of caspase-3 activation and the cleavage of PARP. The effect of formononetin
was also investigated in vivo, where suppression of tumor growth in xenograft mice was
observed after intraperitoneal injection.
Psorospermin is a xanthone present in the roots and stembark of the African plant
Psorospermum febrifugum, where it occurs in the (2′R,3′R)-configuration [138]. Fellows et al.
synthesized all four enantiomers of the compound and tested them for their effect on several
cancer cell lines, including RPMI8226, RPMI8226S, RPMII8226/DOXIV, and RPMI8226/D40
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cells. Of all four enantiomers, the naturally occurring (R,R)-enantiomer was the most potent
with IC50 values of 0.072, 0.036, 0.097, and 0.037 µM, respectively, after 96 h of incubation.
The pronounced effect against doxorubicin-resistant RPMI8226/D40 cells was further in-
vestigated by Carey et al., who found that the retention of doxorubicin was enhanced after
pretreatment with psorospermin [139]. As overexpression of P-glycoprotein is the main
reason for doxorubicin-resistance, the authors conclude that the effect is due to mdr1/P-
glycoprotein inhibition. Even more so, as neither transcription of mdr1 nor translation of
P-glycoprotein were downregulated after application of the compound.
Mangiferin, a C-glucosyl xanthone, was investigated by Takeda et al. for its effect on
RPMI8226 cell line [140]. The compound, that is known from plants such as Mangifera indica,
was found to inhibit nuclear translocation of NF-kB by decreasing the expression of phos-
phorylated NF-kB-inducing kinase (NIK), XIAP, survivin, and bcl-xL proteins. Mangiferin,
furthermore, inhibited NF-kB activation by increasing the expression of IκB protein. Though
mangiferin also showed promising results in various other cancers, it was not further
promoted due to its limited bioavailability [141]. Thus, current research focuses on the
development of appropriate drug delivery systems, such as mangiferin-integrated polymers.
Three studies investigated the antimyeloma potential of gambogic acid. Gambogic
acid is a caged polyprenylated xanthone and the major active ingredient of gamboge
secreted from Garcinia hanburryi [142]. It exhibited pronounced effects against an array
of different cancers and was therefore attributed promising therapeutic potential [143].
However, poor aqueous solubility and biodistribution combined with multi-targeting
capacity led to unavoidable systemic toxicity [144]. Therefore, numerous studies focused
on the minimization of these side-effects by means of nanotechnology [142,144]. The po-
tential of gambogic acid against MM was evaluated in three studies [145–147]. Yang et al.
investigated the compound’s effect on the proliferation of RPMI8226 cells and determined
an IC50 value of approximately 2.5 µM after 12 h of incubation [145]. The effect was due
to the accumulation of ROS, leading to the activation of caspase 3, cleavage of PARP, and
the downregulation of SIRT1. Pandey et al. investigated the effect of gambogic acid on
MM1S, U266, RPMI8226, and H929 cell lines and found that the compound downregu-
lated the expression of homing receptor CXCR4 by inhibiting NF-kB DNA binding [146].
The direct interaction with CXCR4 was predicted by docking studies and subsequently
confirmed by a quantitative chromatin immunoprecipitation assay, where gambogic acid
inhibited p65 binding as well as phosphorylation of AKT, p38, and Erk1/2. The compound,
moreover, abrogated RANKL- and MM cell induced differentiation of macrophages to
osteoclasts through IL-6 inhibition. Wang et al. studied the effects of gambogic acid on
expression of HIF-1α and its downstream target VEGF in U266 cells, showing that hypoxia-
activated pathways were suppressed by the inhibition of the PI3K⁄AKT⁄mTOR signaling
pathway [147]. As a result, IC50 values under hypoxia were significantly lower (0.4–1.6 µM)
than under normoxic conditions (2.8 µM, both after 8 h of incubation). The compound,
furthermore, decreased tumor volumes in mice by anti-angiogenic activity.
Same as flavonoids, also isoflavones have been subject of numerous pharmacological
studies, but due to their restriction to the Fabaceae family, their abundance is quite lower.
Genistein and formononetin display two major isoflavones, which (like their flavonoid
counterparts) cannot be regarded as compounds with remarkable antimyeloma activity.
In contrast, the rather less abundant group of xanthones yielded two compounds with
pronounced effects, namely psorospermin and gambogic acid. While the latter compound
showed low micromolar IC50 values against RPMI8226 and U266 cells (after only 12 and
8 h of incubation), psorospermin was even inhibiting normal and doxorubicin-resistant
RPMI8226 cells with IC50 values ranging from of 36 to 97 nM (even though the incubation
time of 96 h was quite long). Thereby, it was shown that psorospermin was not only acting
through the abovementioned P-glycoprotein inhibition but also through topoisomerase
II-mediated alkylation by its side chain [139].
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3.2.8. Gallic Acid Derivatives
This section deals with gallic acid and four of its derivatives, of which two are galloyl-
catechins and two are galloylglucoses (Figure 10).
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myeloma cells yi lded 97 out of 2 00 marketed natural products [153]. Of th se 97 com-
s theaflavin digal ate was chosen for further validation, during which IC50 values of
0.59 µM (ARP1) and 0.27 µM (KMS11) were determined.
seeleesuren et al. investigated pentagal oyl glucose (1,2,3,4,6-penta-O-gal oyl-beta-D-
glucopyranoside), a polyphenol f und in numerous herbs, for its effect on RPMI8226, U266,
and H929 cells [154]. IC50 values for the three cell lines were determined with 23.9, 36.2, and
10.2 µM, respectively, after 72 h of incubation. Thereby, the compound induced caspase 3
activity, and decreased MYC expression, a proto-oncogene that is frequently hyperactivated
in MM. Additionally, pentagalloyl glucose lowered mRNA levels and reversed the mRNA
expression of MYC target genes such as p21, p27, and cyclin D2. Additionally, in this study,
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the effect of bortezomib was antagonized in combination treatment, as has already been
described for other polyphenols [55].
Though all five compounds of this subsection display tanning agents, they differ not
only by their molecular weights but also by the type of gallic acid derivatives, with two
compounds showing a central glucose molecule and two others a flavan-type scaffold. Of
the latter type is theaflavin digallate, which consists of two condensed flavanols with two
attached gallic acids, and by far shows the highest antiproliferative potential. Still, the type
of derivative does not seem to be the sole responsible criteria, which becomes evident by
the only moderate activity of epigallocatechin gallate, the second flavan-type derivative.
3.3. Terpenes
3.3.1. Sesquiterpenes
Seven sesquiterpene monomers, of which five belong to the subclass of sesquiterpene
lactones, and one sesquiterpene dimer will be discussed in this section (Figure 11).
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was found to induce cytochrome C release, to activate caspases, and to induce PARP
cleavage. β-sesquiphellandrene also downregulated cell survival proteins such cFLIP,
bcl-xL, bcl-2, c-IAP1, and survivin, while the lack of NF-κB-p65 protein had no effect on
the activity. Additionally, the compound was found to be synergistic with the myeloma
drugs bortezomib and thalidomide.
(+)-8-hydroxycalamenene, a compound present in the traditional Korean medicinal
plant Reynoutria elliptica, was studied on U266 cell lines [155]. The compound blocked
constitutive STAT3 activation through the inhibition of upstream kinases JAK1/2 and c-Src.
(+)-8-hydroxycalamenene, moreover, inhibited the expression of gene products involved in
the counteraction of apoptosis (bcl-2 and bcl-xL), proliferation (cyclin D1), and invasion
(MMP-9) and potentiated the apoptotic effect of bortezomib.
Parthenolide is a sesquiterpenoid and known NF-κB inhibitor present in the feverfew
plant (Tanacetum parthenium) [156]. It contains an α-methylene-γ-lactone ring and an epox-
ide group that are able to interact with nucleophilic sites of biological molecules. Apart
from the covalent reaction, parthenolide was found to modulate microtubule dynamics
by interfering with the detyrosination of α-tubulin [157]. The compound showed pro-
nounced effects against several cancer cell lines and seems to be a promising candidate
for multimodal therapies [156,157]. MM inhibitory activity of parthenolide was tested on
MM1S, MM1R, H929, U266, RPMI8226, and RPMI8226/Dox-resistant cells, showing IC50
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values between 1 and 3 µM on all cell lines after 72 h of incubation [158]. The compound
blocked IL-6 secretion from bone marrow stromal cells, rapidly induced caspase activation
and cleavage of PARP, MCL-1, XIAP, and BID. Parthenolide, moreover, showed additive
and synergistic effects when combined with dexamethasone and TNF-related apoptosis-
inducing ligand, respectively. Gunn et al. investigated the compound’s effect on the
apoptosis of RPMI8226 and U266 cells and determined EC50 values of around 25 µM after
18 h of incubation [159]. Parthenolide was also studied for its effect on MM-cancer stem
cells (MM-CSC), which were selected from the cell lines via the potential to form colonies in
methylcellulose. Thereby, MM-CSC showed preferential cytotoxicity compared to non-CSC
myeloma cells. Addition of the bone marrow stromal compartment did not abrogate the
effect. Parthenolide was investigated in a phase I dose escalation trial of feverfew extract
in patients with cancer [160]. Thereby, doses equivalent to 1, 2, 3, and 4 mg parthenolide
were applied as tablets and plasma levels of the compound were measured using liquid
chromatography coupled to mass spectrometry. In this study, no significant toxicity was
observed; however, no relevant plasma concentrations (>0.5 ng/mL) of parthenolide could
be detected.
Alantolactone, which is present in the root of the medicinal plant Inula helenium was
subject of numerous anticancer studies and found to affect different signaling pathways,
namely p38, STAT3, NF-κB, and AKT [161]. The effect on myeloma cells was tested on
OPM2, MM1S, MM1R, U266, H929, RPMI8226, and RPMI8226/BTZ-resistant cell lines,
with IC50 values between 3 and 6 µM after 48 h of incubation [162]. The compound
inhibited cell growth in the presence or absence of bone marrow-derived stromal cell
line (HS-5) by caspase-3 activation and down-modulation of the activation of ERK 1/2.
Alantolactone, furthermore, reduced the secretion of MM survival and growth-related
cytokines and inhibited cytokine-induced osteoclastogenesis.
Bigelovin, a sesquiterpene lactone present in the traditional Chinese medicinal plants
Inula britannica and Inula helianthusaquatilis, was studied on U266, RPMI8226, MM1S, and
MM1R cells where it exhibited antiproliferative effects with IC50 values between 0.5 and
0.99 µM after 24 h of incubation [163]. Mechanistically, the compound caused cell cycle
arrest and inducted apoptosis by proteolysis of E2F1, which was overexpressed in 25–57%
of MM patients investigated.
6-O-angeloylplenolin, a sesquiterpene lactone isolated from Centipeda minima, was
tested for its apoptotic effect on MM1S, U266, and RPMI8226 cells, showing EC50 values of
approximately 7.5 µM after 48 h of incubation. The effect was associated with caspase-3
and PARP cleavage [164].
Cnicin, which is present in species of the genus Centaurea [165], was investigated for its
antiproliferative effect on RPMI8226, U266, H929, OPM2, LP1, MM1S, and MM1R cells [166].
The compound showed IC50 values between 3 and 13 µM after 48 h of incubation. Thereby,
cnicin acted via downregulation of Pim-2, a serine/threonine kinase that is highly expressed
in malignant but not in normal plasma cells. The cytotoxic effect was accompanied by
activation of caspases, accumulation of reactive oxygen species and downregulation of
NF-κB and was confirmed in co-culture with stroma cells as well as in an ex vivo chicken
chorioallantoic membrane assay. Additionally, the combination of cnicin with myeloma
drugs (melphalan, bortezomib, AKT-inhibitor) led to enhanced cell death.
Gossypol, the last compound of this section, is usually extracted from cotton
plants [167–169]. The compound was first used as male contraceptive but was subse-
quently studied for its potential use against cancer, where it mainly targets bcl-2 family
proteins [169]. Though gossypol appears like (and ultimately ends up as) a polyphenolic
compound, biosynthetically it is a dimeric sesquiterpenoid and therefore discussed in this
section [170]. Lin et al. studied the effect of gossypol on U266 cells and determined IC50
values of 9.0, 2.4, and 0.9 µM after 24, 48, and 72 h of incubation [167]. The compound
induced apoptosis via activation of caspase-3 and caspase-9 as well as decreased expression
of bcl-2 and bcl-xL. In vivo studies in BALB/c mice showed that growth inhibition of
about 30% was obtained after administration of gossypol. Sadahira et al. investigated the
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compound’s behavior against U266 cells and showed that beside caspase-3 activation also
cytochrome c release from mitochondria was induced [168]. Further studies showed that
gossypol suppressed IL-6 signals, indicated by the inhibition of JAK2-, STAT3-, ERK1/2-,
and p38-phosphorylation. The effect of gossypol was found to depend on the displace-
ment of BH3-only proteins from bcl-2 and on the inhibition of IL-6 signaling, ultimately
cumulating in bcl-2 dephosphorylation and Mcl-1 downregulation.
Of the eight investigated sesquiterpenes, seven compounds showed antiproliferative
effects in the micromolar range or even below, such as bigelovin or also gossypol after 72 h
of incubation. Though the effect of sesquiterpenes is often explained by the presence of an
alkylating exocylic methylene group, this structural feature cannot display the sole criteria,
as it is lacking in half of the effective compounds described in this section.
3.3.2. Diterpenes
This section deals with eight diterpenoids of which five show quinone or quinone-like
substructures (Figure 12).
Andrographolide is a diterpene lactone isolated from Andrographis paniculata and in-
hibits the development of different types of cancer by regulation of Wnt/β-catenin, mTOR,
VEGF-mediated intracellular signaling and TRAIL-mediated apoptosis [171,172]. Its MM
inhibitory properties were investigated together with the sesquiterpene lactone partheno-
lide [159]. In this study, which was discussed in the section above, andrographolide induced
apoptosis of both RPMI8226 and U266 cells with the same efficacy as parthenolide (EC50
values of 25 µM after 18 h of incubation). The compound also showed preferential toxicity
toward MM-CSCs over non-tumorigenic MM cells. However, in contrast to parthenolide,
the addition of the bone marrow stromal compartment abrogated andrographolide activity.
Tanshinone IIA, a diterpenoid with an ortho-quinone substructure, is one of the bioac-
tives from the traditional Chinese medicinal herb Salviae miltiorrhiza and known to display
anticancer activity [173]. The compound was investigated for its antimyeloma effect on
U266 cells, where it significantly increased the expression of microtubule-associated protein
light chain 3 (LC3) II and thus induced autophagic cell death [174]. In KBM5 leukemia cells,
tanshinone IIA, augmented the phosphorylation of AMPK and attenuated the phosphory-
lation of mTOR and p70 S6K. The compound also dramatically activated the ERK signaling
pathway including Raf, ERK, and p90 RSK in both dose- and time-dependent manner.
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studied for its effect on the proliferation of myeloma patient-derived MUM24 cells, which
were inhibited with an IC50 value of 0.65 µM after 48 h of incubation.
The diterpene quinone 6-acetylfredericone B and the two-quinone like diterpenoids
coleon G and O were tested on MM-CSC and RPMI226 cells [176]. The three compounds,
which were isolated from Plectranthus scutellarioides, showed IC50 values of 17.6, 37.4, and
9.2 µM, respectively, against MM-CSC cells as well as values of 21.6, 38.4, and 8.4 µM,
respectively, against RPMI8226 cells. The compounds were also evaluated for their abil-
ity to inhibit NF-κB, which was determined with IC50 values of 11.2, 11.0, and 9.7 µM,
respectively.
Forskolin is a labdane type diterpenoid present in the roots of the Indian plant Coleus
forskohlii, which has been used for centuries in Hindu Ayurvedic medicine [177]. It is
known to raise intracellular cAMP levels and has been found active against a variety
of cancers. Forskolin has been tested for apoptosis induction in myeloid U266, H929,
RPMI8226, OPM2, and INA6 cells, with EC50 values of approximately 80 µM for H929 and
RPMI8226 cells as well as values of around 4 µM for U266, OPM2, and INA6 cells [178].
However, the main objective of this study was the investigation of therapeutic synergism of
the cAMP-elevator forskolin and melphalan, cyclophosphamide, doxorubicin, bortezomib,
and dexamethasone. It was shown that forskolin potentiated the killing induced by all
the tested agents. Thereby, the combination with dexamethasone was found to be at least
partly mediated by the proapoptotic bcl-2 family member BIM.
Oridonin, a highly oxidated diterpenoid of the kauran-type, was isolated from Isodon
rubescens, also referred to as Rabdosia rubescens [179–181]. The compound showed anti-
angiogenic and antimetastatic properties against, e.g., breast, pancreatic, lung, colon,
and skin cancer and was subsequently used as natural lead. Thereby, semi-synthetic
approaches were focusing on modifications of the A-ring of the molecule or esterification
of the hydroxyl group in position 14 [181]. With regard to MM, oridonin was investigated
for its effect on the proliferation of RPMI8226 and RPMI8226/BTZ-resistant cells [179].
IC50 values were determined with 7.1 and 229.5 nM, respectively, after 48 h of incubation
and were in the range of bortezomib (7.3 and 231.9 nM, respectively). Mechanistically,
the compound sensitized MM cells via the PTEN/PI3K/AKT pathway, activating the
expression of PTEN, a negative regulator of the PI3K/AKT pathway, while inhibiting the
expression of p-AKT.
Not only sesquiterpenes, but also the subclass of diterpenes do provide a range
of interesting compounds, among which komariviquinone and oridonin are certainly
the most interesting candidates. Both compounds exhibited antiproliferative effects at
submicromolar concentrations, whereby oridonin even showed a low nanomolar IC50 value
against the normal RPMI8226 cell line and was even efficiently inhibiting BTZ-resistant
RPMI8226 cells.
3.3.3. Triterpenes
This section discusses 14 triterpenoids, of which seven compounds display triterpene
glycosides (Figure 13).
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uassinoid present in diff rent Brucea sp cies, was investigated on MM
a - SC cells [182,183]. Quass noids are exclusive for the Simaroubaceae family
and are bitter tasting co stituents, which biogenetically can be regarded as d graded
triterpenoids [184]. Cuendet t al. studied the effect of bruceantin on the apoptosis
of RPMI8226, U266, and H929 cells, determining EC50 values of 13, 49, and 15 nM,
respectively [182]. Interestingly, the c mpound strongly downregulated c-MYC in the
RPMI8226 cell line, but not in U266 or in H929 cells. Apoptosis resulted from proteolytic
processing of procaspases and degradation of PARP and involved the mitochondrial
pathway. The apoptotic effect of bruceantin on RPMI8226 cells was, further ore, studied in
a mouse xenograft model, where the compound led to significant regression of tumors. A
study of bruceantin on MM-CSC cells found that the compound inhibited cell proliferation
with an IC50 of 77 nM [183]. Moreover, bruceantin induced cell cycle arrest and apoptosis in
MM-CSCs starting at a concentration of 25 nM. The compound also inhibited cell migration
and angiogenesis presumably via the Notch pathway.
Two more triterpene lactones, withaferin A and withanolide F, were isolated from
the leaves of Withania adpressa, a Moroccan endemic species and local remedy for the
treatment of food intoxication [185]. Both compounds were found to inhibit proliferation
of RPMI8226 and MM-CSC cells, with IC50 values of 0.2 and 0.3 µM (withaferin A) and 0.1
and 5.3 µM (withanolide F), respectively, after 72 h of incubation. Both compounds also
inhibited NF-κB activity with IC50 values of 0.05 and 1.2 µM, respectively.
Betulinic acid, a pentacyclic triterpene of the lupane-type, was first isolated from Zizi-
phus mauritiana, which is meanwhile classified as Ziziphus jujuba, but is known to be present
in various other plants, e.g., species of the birch tree (Betula) [186–188]. Though betulinic
acid was found to possess some anticancer activity, it was rather suggested for combination
therapies or as subject for further chemical modification, such as the semi-synthesis of more
potent triphenylphosphonium derivatives [188,189]. The compound was studied for its
antimyeloma effect on U266 and MM1S cell lines, where it inhibited constitutive activation
of STAT3, c-Src kinase, JAK1 and JAK2 at a concentration of 50 µM [186]. Betulinic acid
downregulated the expression of STAT3-regulated gene products such as bcl-xL, bcl-2,
cyclin D1, and survivin, and induced the expression of the protein tyrosine phosphatase
SHP-1. The compound’s antiproliferative effect was determined with IC50 values of 20 µM
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against U266 cells and 30 µM against MM1s cells, both after 72 h of incubation. Betulinic
acid, additionally, enhanced the apoptosis in myeloma cells induced by thalidomide and
bortezomib. Shen et al. investigated the effect of betulinic acid on U266 and RPMI8226
cells and found that the compound mediated cytotoxicity through induction of apoptosis
(with an EC50 value of approximately 40 µM after 12 h of incubation), S-phase arrest,
mitochondrial membrane potential collapse, and overwhelming ROS accumulation [187].
ROS overproduction directly resulted from inhibition of the NF-κB pathway, the latter
mechanism was also demonstrated in a mouse xenograft model. Another xenograft model
showed that betulinic acid initiated different types of cell death and that PPA2 was acting
as a switch to regulate between apoptosis and autophagy [190].
Celastrol is an oleanane type triterpenoid, which has been isolated from the Chinese
medicinal plant Tripterygium wilfordii (Thunder of God) about four decades ago [191]. It has
been extensively studied for its anticancer activity [192–194], not only from mechanistic
point of view but also to increase its potency through semi-synthetical modifications or
the use of drug delivery systems [195,196]. Celastrol was studied for the growth inhibition
of U266 cells, showing an IC50 value of 0.5 µM after 24 h of incubation [197]. It induced
apoptosis of myeloma cells via activation of caspase-3 and blocking of NF-κB pathway.
A study on the inhibition of c-Myc-Max heterodimers revealed celastrol as an inhibitor
of the c-Myc protein, which is overexpressed in human cancers including myeloma [198].
However, due to the reactive quinone methide substructure of the compound, the inhibition
did not result from prevention of dimerization but from directly altering the quaternary
structure of the pre-formed dimer. Thus, the inhibition of c-Myc was less specific compared
to triterpenoids lacking the quinone methide feature, but more potent.
An earlier study investigated the effect of pristimerin, which is the methyl ester of
celastrol and present in several species of the Celastraceae and Hippocrateaceae fami-
lies [199]. The compound exhibited antiproliferative effects against a variety of cancer
cell lines, with IC50 values in the low and sub-micromolar range. Pristimerin, which
was detected in a chemical library search, was tested for its antiproliferative effect on
various myeloma cell lines showing sub-micromolar IC50 values after 72 h of incubation
(Table 1) [200]. Moreover, pristimerin was found to act via inhibition of phosphorylation of
IκB, thereby stabilizing the inactive IκB/NF-κB complex as well as by causing an unfolded
protein response in tumor cells and thus markedly suppressing NF-κB activity and cyclin D
expression. Inhibiting both, proteasome chymotrypsin-like activity and NF-κB, pristimerin
induced selective apoptosis with greater potency than other antineoplastic triterpenoids
providing the rationale for pharmaceutical development of triterpenoid dual-function
proteasome/NF-κB inhibitors. However, the abovementioned reactivity of celastrol (and
the thus resulting unwanted pharmacological effects) also accounts for pristimerin, which
shows exactly the same quinone methide substructure [198].
Ursolic acid, an ursane type triterpenoid, has been reported from numerous plant
species and has been found to exert anticancer activity via mitochondria-dependent path-
ways [201,202]. Same as betulinic acid, the compound was studied for possible chemical
or nanotechnological modifications in order to enhance its therapeutic effects [201,203].
With regard to MM, ursolic acid was studied for its effect on U266, MM1S, and RPMI8226
cells [204]. The compound inhibited constitutive and IL-6 induced STAT3 activation
through the inhibition of activation of upstream kinases c-Src, JNK1/2, and ERK1/2. Ur-
solic acid, furthermore, downregulated the expression of STAT3-regulated gene products
such as cyclin D1, bcl-2, bcl-xL, survivin, and Mcl-1, and induced the expression of tyro-
sine phosphatase SHP-1. Additionally, the compound potentiated the apoptotic effects of
thalidomide and bortezomib. A more recent study found that ursolic acid interacted with
deubiquinating protease USP7 in RPMI8226 cells, showing an IC50 value of 7 µM [205]. The
antiproliferative effect was determined with an IC50 of 26.5 µM after 24 h of incubation.
Asiaticoside is an ursolic acid derivative, showing additional hydroxylation, demethy-
lation and foremost a trisaccharidic moiety, which is attached to the carboxyl group. The
compound was tested on KM3/BTZ-resistant cells, where it exhibited an IC50 value of
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12 µM after 48 h of incubation [206]. Same as ursolic acid, asiaticoside was found to act
via modulation of the STAT3 pathway. Additionally, an increase of ROS levels as well as
an upsurge in the expression of LC3-II was observed, which accompanied autophagic cell
death induced by the compound.
Six more triterpene glycosides with antimyeloma properties were detected in black
cohosh, a traditional remedy for the alleviation of mild climacteric complaints [207]. Due
to the complex metabolite pattern of black cohosh triterpenoids, three representative
compounds for the respective substructures were initially tested on H929, OPM2, and
U266 cells, uncovering the cimigenol type as the most active substructure. Subsequent
evaluation of the apoptotic effect of four cimigenol derivatives showed EC50 values from
20 µM upwards after 24 h of incubation, however, with only slight selectivity compared to
healthy PBMCs.
The subclass of triterpenes yielded several compounds with submicromolar IC50 val-
ues, three of them displaying a lactone ring (bruceantin, whitaferin A, and whitanolid F).
This structural feature often also occurs in sesquiterpenes, which are then named sesquiter-
pene lactones. However, the latter group of compounds usually shows a pentacyclic lactone
ring in contrast to the six-membered lactone ring present in the mentioned triterpenes.
Out of these, the quassinoid bruceantin revealed the highest antiproliferative potential,
with an even low nanomolar IC50 value against RPMI8226 cells. Additionally, celastrol
and pristimerin, exhibited good inhibitory effects, as demonstrated on a variety of cell
lines for the latter compound. Both, celastrol as well as pristimerin possess a quinone
methide substructure and thus not only act via NF-κB but also show proteasome-inhibiting
properties. However, this structural feature may also lead to unwanted pharmacological
side effects, such as the formation of Michael adducts.
3.3.4. Other Terpenes
This section comprises the monoterpene thymoquinone and crocin, the only tetrater-
penoid with reported antimyeloma activity (Figure 14).
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the compound was investigated for its antiproliferative effect on U266 and RPMI8226 cells,
with IC50 values below 10 µM after 12 h of incubation [208]. Thymoquinone inhibited
both constitutive and IL-6-inducible ST T3 phosphorylation, hich correlated with the
inhibition of c-Src and JAK2. Moreover, the compound was found to induce the expression
of Src homology-2 phosphatase 2 that correlated with suppression of STAT3 activation and
resulted in the downregulation of the expression of STAT3-regulated gene products, such
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as cyclin D1, bcl-2, bcl-xL, survivin, Mcl-1, and VEGF. In addition, the apoptotic effect of
thalidomide and bortezomib was potentiated in combination treatment with thymoquinone.
The tetraterpenoid crocin is one of the main active principles in saffron (Crocus
sativus) [212]. Due to the use of saffron as spice, the compound was as well subjected
to several studies investigating its anticancer and chemopreventive effects [212,213]. With
regard to MM, crocin was studied for its effect on U266 cells and effectively suppressed con-
stitutive STAT3 activation through the inhibition of activation of protein tyrosine kinases
JAK1, JAK2, and c-Src [214]. The compound furthermore suppressed the translocation of
STAT3 to the nucleus and induced the expression of tyrosine protein phosphatase SHP-1.
Crocin also downregulated the expression of STAT3-mediated gene products including
bcl-2, BAX, CXCR4, VEGF, and cyclin D1.
Though both compounds derive from different compound subclasses, namely mono-
and tetraterpenes, they do act via inhibition of the STAT3 pathway demonstrating how
various chemical structures can still show similar mechanisms of action, as observed
repeatedly during this review.
4. Summary and Conclusions
A total of 92 compounds with reported activity on at least one human myeloma cell
line were found in literature (until the end of 2020) and discussed in this review. Thereby,
each of the three main compound classes (alkaloids, phenolics, terpenes) yielded one or a
few interesting compounds, which deserve special attention. For the class of alkaloids, the
naphtylisoquinolin dioncophyllin A is pointed out, which induced apoptosis with an EC50
in the nanomolar range without showing significant toxicity. In addition, some of its natural
derivatives did exhibit similar effects in the low micromolar range. From a chemical point
of view, dioncophyllines are stable (with only a few compounds showing racemization)
and thus can be produced by chemical synthesis, as demonstrated by Li et al. [24].
The two phenolic compounds theaflavin digallate and psorospermin similarly demon-
strated antiproliferative potential in the nanomolar range, the latter compound affecting
doxorubicin-resistant cells to comparable extent [138]. Additionally, of interest is the fact,
that of four possible stereoisomers, the naturally occurring (R,R)-form was the most active,
demonstrating the importance of correct stereochemical attribution when dealing with nat-
ural products as well as the stereoselectivity of pharmacological effects. Another xanthone
derivative, namely gambogic acid is also worth mentioning. Although the compound’s an-
tiproliferative effects were in the micromolar range (at least under normoxic conditions), it
effectively suppressed hypoxia-activated pathways which might be important in vivo [147].
Consequently, gambogic acid was subject of additional studies evaluating its efficacy in
combination therapies with bortezomib and other chemotherapeutics [142,215,216]. With
regard to clinical trials, a phase IIa study comparing the efficacy and safety of different
dosage schedules of gambogic acid in patients with advanced malignant tumors was
reported [217]. Although no significant difference in the objective response rate (which
was defined as primary endpoint) could be calculated, the greater disease control rates
in the verum group suggest a favorable safety profile for gambogic acid at a dose of
45 mg/m2. The class of terpenoids shows a range of interesting constituents, such as the
highly oxygenated diterpenoid oridonin, which exhibited antiproliferative effects equal to
those of bortezomib on RPMI8226 cells [179]. The quassinoid bruceantin as well showed
low nanomolar IC50 values in RPMI8226 cells and inhibited MM-CSC in a nanomolar
range [182,183], a fact that was also observed for withaferin A and withanolide F [185]. All
three compounds are lactones, but also share the structural feature of a cyclohexenone ring,
which might be a crucial functional group for the compounds’ activity. This hypothesis is
corroborated by comparing the structures of celastrol and pristimerin, which also exhibited
noteworthy effects [197,198,200]. Both compounds contain a structural analogue of the
cyclohexenone ring, namely a quinone methide substructure, and showed proteasome as
well as NF-κB inhibiting properties.
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Thus far, four review articles dealing with MM and natural products were pub-
lished [218–221]. Issa et al. focused on MM-CSCs and the most relevant stem cell char-
acteristics such as resistance, self-renewal, differentiation, and migration [218]. Thereby,
the key cellular signaling pathways were discussed and 17 natural products targeting
hematological CSCs were presented. Kang et al. displayed different mechanisms by which
natural products are known to exhibit their effects, e.g., induction of apoptosis, cell cycle
arrest, anti-angiogenesis, and regulation of miRNAs [219]. For each mechanism, a set
of active phytochemicals is highlighted, altogether discussing 23 single compounds and
several plant extracts. Pojero et al. focused on natural polyphenols and presented a total of
18 components, which were discussed with regard to their biological effects and the affected
signaling pathways [220]. In addition, the chemical synthesis of most of the compounds
was depicted. The most recent review on natural products with MM inhibitory activity
was written from a clinical point of view, listing possible therapeutic effects and conducted
clinical trials for 23 single components and a few extracts [221]. Although the title of the
review suggests dealing with dietary agents for MM chemoprevention and treatment,
many of the discussed compounds rather derive from medicinal than edible plant species.
Even though all four reviews reveal interesting findings, they all show only a selection of
natural products with MM inhibitory activity. Thus, the present review article is the first
one summarizing all plant natural products with demonstrated activity against human
myeloma cell lines.
However, looking at the collected data it becomes evident that the reported literature
derives from two different research areas, comprising phytochemical studies on the one
hand and pharmacological investigations on the other hand. Thus, compounds with good
initial results in testing proliferation and viability (e.g., dioncophylline A) are often not
further investigated, whereas other constituents with only moderate activity are subjected
to repeated pharmacological assays; alas, not seldom including unnecessary in vivo studies.
This situation is likely due to the limited number of isolated substances available from
phytochemical studies, which then restrict the execution to only one or a few convenient
assays that were already used for the evaluation of fractions during the isolation procedure.
In contrast, many pharmacological studies are conducted with commercially available sub-
stances, which do not have to be isolated from natural sources but can be readily ordered.
Thus, the provision of larger amounts of substance is feasible (and affordable) allowing
extensive investigations. Here, stronger co-operation between phytochemists and pharma-
cologists is desirable to eventually include the rare “hits” into subsequent pharmacological
studies. Another option would be the collaboration with medicinal/organic chemists if the
substances can be prepared synthetically.
The many studies on well-known natural compounds, however, are still important.
Firstly, the more detailed characterization of pathways contributes essentially to the under-
standing of the compounds’ mechanism of action, which usually also applies for related
derivatives (as observed in this review). Secondly, as mentioned in the introduction, natural
products still lay the basis for the majority of novel anticancer therapeutics and several
anticancer drugs currently on the market or in clinical trials are of plant origin [13,222].
Especially, semi-synthetic derivatives continuously reveal potent anticancer drugs and
therefore are of ongoing interest and subject of recent studies and reports [223,224]. An-
other fact that becomes evident when looking at the literature on anticancer drugs is that
various compound classes afford potent candidates [225], which was also a finding of the
present review. Thirdly, many of the investigated compounds are part of our nutrition,
such as the heteroaliphatic and polyphenolic compounds discussed here. Knowledge on
the mode of action for these substances may help to elucidate cancer chemopreventive
properties, which are often postulated for dietary natural products [14,221]. This accounts
especially for polyphenols, which are among the most studied compounds. However,
many polyphenolic compounds, such as flavonoids and tannins, undergo rapid metaboliza-
tion (e.g., glucuronidation) and degradation in the human gut [226,227]. Therefore, direct
relation of eventual chemoprotective effects of these compounds with in vitro or in vivo
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results is difficult and especially depending on the route of administration. In addition, not
only polyphenolics experience metabolic changes in vivo, but so do other compounds, as
observed for a dose escalation trial of parthenolide, where no detectable amounts of the
compound were found in human plasma after oral administration of up to 4 mg [160].
From the cell biological point of view, the investigations on pathways in these studies
appear to be mostly conducted along the ones already known to have an impact on
myeloma cells. For several studies, readouts are limited to effects on proliferation and
viability and therefore a profound summary or classification is not feasible.
Certainly: killing the bulk of myeloma cells, eradicating the myeloma stem cells and
reconstituting a cancer-hostile microenvironment is a task that is hardly accomplished by a
single compound. Natural products have attracted attention due to their large number of
biological activities, fewer side effects, and high safety aspects. Utilizing recently designed
culture setups (e.g., 3D co-cultures, humanized mouse models) and taking advantage of
the development of sophisticated methods and approaches (e.g., proteomics, single cell
sequencing) that enable complex experimental readouts, as well as the increasing availabil-
ity of “real world” expression data from patients’ samples, will essentially contribute to
further the success of natural compounds in anticancer research.
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